Zenapax

Company: Roche
Approval Status: Approved December 1997
Treatment for: rejection of kidney transplants
Areas: Diabetes / Endocrinology; Urology & Kidneys

| General Information | Clinical Results |

General Information

Hoffman-La Roche's new monoclonal antibody drug, Zenapax (daclizumab), has been approved to prevent rejection of kidney transplants. The drug uses the body's own immune system to prevent the acute rejection that can make kidney transplants fail.

Clinical Results

The FDA said its approval was based on two clinical trials that showed Zenapax significantly reduced acute rejections in patients who got the drug along with the standard three-drug cocktail of immunosuppressant drugs. Patients on Zenapax had 37 to 40% fewer rejections episodes than those given an inert placebo.

< back to top

Zenapax Drug Information

The Zenapax drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.